TetraLogic Pharmaceuticals Corp banner

TetraLogic Pharmaceuticals Corp
OTC:TLOG

Watchlist Manager
TetraLogic Pharmaceuticals Corp Logo
TetraLogic Pharmaceuticals Corp
OTC:TLOG
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: $24.5

Relative Value

TLOG latest financial reports are more than 6 years old.
TLOG doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of TLOG.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TLOG Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

TLOG Competitors Multiples
TetraLogic Pharmaceuticals Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
TetraLogic Pharmaceuticals Corp
OTC:TLOG
24.5 USD 0 -0 -1.2 -1.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
407.7B USD 6.7 97.4 16 22.2
US
Astria Therapeutics Inc
NASDAQ:ATXS
326.4B USD 462 374.5 -2 631.9 -2 389.6 -2 389.6
US
Amgen Inc
NASDAQ:AMGN
208.4B USD 5.7 27 15.4 15.4
US
Gilead Sciences Inc
NASDAQ:GILD
185.3B USD 6.3 21.8 14.8 14.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
125.9B USD 10.5 31.8 24.4 25.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.7 18.3 13.7 15.7
AU
CSL Ltd
ASX:CSL
71.1B AUD 3.2 16.7 11.5 14.3
NL
argenx SE
XBRU:ARGX
39.9B EUR 13.1 30.9 52.4 53.9
P/S Multiple
Revenue Growth P/S to Growth
US
TetraLogic Pharmaceuticals Corp
OTC:TLOG
Average P/S: 3 415 539
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Astria Therapeutics Inc
NASDAQ:ATXS
462 374.5
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5.7
3%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
6.3
5%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
11%
1
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
NL
argenx SE
XBRU:ARGX
13.1
49%
0.3
P/E Multiple
Earnings Growth PEG
US
TetraLogic Pharmaceuticals Corp
OTC:TLOG
Average P/E: 34.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
97.4
96%
1
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 631.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
27
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.8
14%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.8
17%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
NL
argenx SE
XBRU:ARGX
30.9
42%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
TetraLogic Pharmaceuticals Corp
OTC:TLOG
Average EV/EBITDA: 21.2
Negative Multiple: -1.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
12%
1.3
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 389.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.4
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
14.8
16%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
18%
0.8
AU
CSL Ltd
ASX:CSL
11.5
7%
1.6
NL
argenx SE
XBRU:ARGX
52.4
828%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
TetraLogic Pharmaceuticals Corp
OTC:TLOG
Average EV/EBIT: 23.1
Negative Multiple: -1.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.2
24%
0.9
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 389.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.4
3%
5.1
US
Gilead Sciences Inc
NASDAQ:GILD
14.8
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.7
23%
0.7
AU
CSL Ltd
ASX:CSL
14.3
10%
1.4
NL
argenx SE
XBRU:ARGX
53.9
N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett